ESATENOLOL

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H22N2O3
Molecular Weight	266.3361
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)NC[C@H](O)COC1=CC=C(CC(N)=O)C=C1

InChI

InChIKey=METKIMKYRPQLGS-LBPRGKRZSA-N

InChI=1S/C14H22N2O3/c1-10(2)16-8-12(17)9-19-13-5-3-11(4-6-13)7-14(15)18/h3-6,10,12,16-17H,7-9H2,1-2H3,(H2,15,18)/t12-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C14H22N2O3
Molecular Weight	266.3361
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.google.com/patents/WO1991007175A1 | https://www.ncbi.nlm.nih.gov/pubmed/8383518 | https://www.deepdyve.com/lp/springer-journals/s-atenolol-launched-in-india-XooPAPBH0g | http://www.medclik.com/General/pages/Drugmanual/BrandSearch8/ADBETA.asp

Esatenolol is the (S) enantiomer of atenolol, a beta1-adrenergic receptor antagonist. Only (S)-atenolol, but not (R)-atenolol, contributes to the beta-blocking effect of currently used racemic atenolol since the same effect can be elicited with the (S)-enantiomer alone. Pure (S)-atenolol has been launched in India for the treatment of hypertension and angina pectoris.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-1 adrenergic receptor 158 Target ID: CHEMBL213 Sources: https://www.google.com/patents/WO1991007175A1 \| https://www.ncbi.nlm.nih.gov/pubmed/8383518	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Hypertension 567 Sources: http://www.medclik.com/General/pages/Drugmanual/BrandSearch8/ADBETA.asp http://www.ndrugs.com/?s=esatenolol&t=dosage http://www.drugsupdate.com/generic/view/462/S-Atenolol	Primary	Approved 8429	ADBETA Approved Use This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is also used to treat chest pain (angina) and to improve survival after a heart attack.
Angina pectoris 106 Sources: http://www.medclik.com/General/pages/Drugmanual/BrandSearch8/ADBETA.asp http://www.ndrugs.com/?s=esatenolol&t=dosage http://www.drugsupdate.com/generic/view/462/S-Atenolol	Primary	Approved 8429	ADBETA Approved Use This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is also used to treat chest pain (angina) and to improve survival after a heart attack.
Myocardial infarction 121 Sources: http://www.medclik.com/General/pages/Drugmanual/BrandSearch8/ADBETA.asp http://www.ndrugs.com/?s=esatenolol&t=dosage http://www.drugsupdate.com/generic/view/462/S-Atenolol	Primary	Approved 8429	ADBETA Approved Use This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This medication is also used to treat chest pain (angina) and to improve survival after a heart attack.

PubMed

Title	Date	PubMed
Infrared spectroscopy of racemic and enantiomeric forms of atenolol.	2007 Aug	17113823
Clinical pharmacology.	2008 Oct	21593978
A comparative study of nebivolol and (S) atenolol on blood pressure and heart rate on essential hypertensive patients.	2010 Dec	21189915
3-[4-(2-Amino-2-oxoeth-yl)phen-oxy]-2-hy-droxy-N-isopropyl-propanaminium 1,1'-binaphthyl-2,2'-diyl phosphate.	2010 Dec 11	21522800
Spectrophotometric method for simultaneous estimation of atenolol in combination with losartan potassium and hydrochlorothiazide in bulk and tablet formulation.	2010 Oct	21180476

Patents

Sample Use Guides

In Vivo Use Guide

12.5-100 mg once daily. The dosing regimen of Esatenolol is set individually. he maximum dose for adults for oral administration is 200 mg/day in 1 or 2 doses.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:13:48 GMT 2023` Edited by `admin` on `Fri Dec 15 16:13:48 GMT 2023`
Record UNII	DPF757BOSR
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ESATENOLOL

Official Name

English

4-((2S)-2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)BENZENEACETAMIDE

Systematic Name

English

ATENOLOL, (-)-

Common Name

English

ESATENOLOL [MART.]

Common Name

English

BENZENEACETAMIDE, 4-((2S)-2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-

Systematic Name

English

S-ATENOLOL

Common Name

English

(-)-ATENOLOL

Common Name

English

(S)-ATENOLOL

Common Name

English

2-(P-((2S)-2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)PHENYL)ACETAMIDE

Common Name

English

ESATENOLOL [JAN]

Common Name

English

BENZENEACETAMIDE, 4-(2-HYDROXY-3-((1-METHYLETHYL)AMINO)PROPOXY)-, (S)-

Systematic Name

English

ATENOLOL, (S)-

Common Name

English

esatenolol [INN]

Common Name

English

Esatenolol [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-VATC

QC07AB11

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

WHO-ATC

C07AB11

Created by admin on Fri Dec 15 16:13:48 GMT 2023 , Edited by admin on Fri Dec 15 16:13:48 GMT 2023

NCI_THESAURUS

C29576

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

Code System Code Type Description

CHEBI

31556

Created by admin on Fri Dec 15 16:13:48 GMT 2023 , Edited by admin on Fri Dec 15 16:13:48 GMT 2023

PRIMARY

PUBCHEM

175540

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

PRIMARY

EPA CompTox

DTXSID10239405

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

PRIMARY

CAS

93379-54-5

Created by admin on Fri Dec 15 16:13:48 GMT 2023 , Edited by admin on Fri Dec 15 16:13:48 GMT 2023

PRIMARY

SMS_ID

100000084564

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

PRIMARY

INN

7337

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

PRIMARY

FDA UNII

DPF757BOSR

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

PRIMARY

DRUG CENTRAL

4702

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

PRIMARY

EVMPD

SUB06608MIG

Created by admin on Fri Dec 15 16:13:48 GMT 2023 , Edited by admin on Fri Dec 15 16:13:48 GMT 2023

PRIMARY

ChEMBL

CHEMBL343633

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

PRIMARY

DRUG BANK

DB13443

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

PRIMARY

NCI_THESAURUS

C81661

Created by admin on Fri Dec 15 16:13:49 GMT 2023 , Edited by admin on Fri Dec 15 16:13:49 GMT 2023

PRIMARY

Related Record Type Details


					YG132I00WY

ATENOLOL, (+)-

ENANTIOMER -> ENANTIOMER

Amount:


					50VV3VW0TI

ATENOLOL

RACEMATE -> ENANTIOMER

Amount:


					4A4MK4KIB5

BETA-1 ADRENERGIC RECEPTOR

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					DPF757BOSR

ESATENOLOL

ACTIVE MOIETY

Amount:

Details

SMILES

InChI

DescriptionSources: https://www.google.com/patents/WO1991007175A1 | https://www.ncbi.nlm.nih.gov/pubmed/8383518 | https://www.deepdyve.com/lp/springer-journals/s-atenolol-launched-in-india-XooPAPBH0g | http://www.medclik.com/General/pages/Drugmanual/BrandSearch8/ADBETA.asp

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Approved Use

Approved Use

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.google.com/patents/WO1991007175A1 | https://www.ncbi.nlm.nih.gov/pubmed/8383518 | https://www.deepdyve.com/lp/springer-journals/s-atenolol-launched-in-india-XooPAPBH0g | http://www.medclik.com/General/pages/Drugmanual/BrandSearch8/ADBETA.asp